查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1974463

GLP-1促效劑市場分析及預測（至2035年）：依類型、產品類型、技術、應用、最終用戶、組件、設備、實施類型、階段及解決方案分類

GLP-1 Agonist Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Component, Device, Deployment, Stage, Solutions
出版日期: | 出版商: Global Insight Services | 英文 447 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計GLP-1促效劑市場將從2024年的530億美元成長至2034年的2,649億美元，複合年成長率約為17.5%。 GLP-1促效劑市場主要由模擬Glucagon-Like Peptide-1激素的藥物組成，這些藥物能夠促進胰島素分泌和血糖調節。這些促效劑主要用於治療第2型糖尿病和肥胖症，在代謝治療中發揮至關重要的作用。受糖尿病和肥胖症盛行率上升、藥物製劑和給藥機制的進步以及治療適應症的擴展等因素的推動，該市場正經歷強勁成長。

GLP-1促效劑市場在全球關稅和地緣政治緊張局勢的影響下，呈現出複雜的市場環境。在日本和韓國，企業正透過增加對本地研發和產能的投資來制定策略，以減輕關稅的影響。中國在出口限制下，正加速推動國內醫藥創新，以確保供應鏈的韌性。台灣在維持其醫藥製造核心地位的同時，也極易受到中美地緣政治緊張局勢的影響。在美國母市場，受糖尿病和減肥藥需求不斷成長的推動，全球市場呈現強勁成長動能。預計到2035年，在策略聯盟和多元化供應鏈到位的前提下，該市場將顯著擴張。中東衝突可能間接影響能源價格，進而影響生產成本和進度。

市場區隔
類型 胜肽類GLP-1促效劑，非胜肽類GLP-1促效劑
產品 注射GLP-1促效劑，口服GLP-1促效劑
科技 重組DNA技術、合成技術、生物技術
適應症 2型糖尿病、肥胖症管理、心血管疾病
最終用戶 醫院、診所、居家醫療機構、研究機構
成分 活性成分、添加物、包裝材料
醫療設備 筆式注射器、預填充式注射器和自動注射器
安裝位置 住院設施、門診設施
步 藥物發現階段、臨床前階段、臨床試驗階段、商業化階段
解決方案 病患依從性解決方案、數位健康平台

在對創新型糖尿病管理方案需求不斷成長的推動下，GLP-1促效劑市場持續穩定擴張。製藥業佔據主導地位，其中注射劑因其卓越的血糖控制效果而佔據主導地位。口服製劑因其便利性和更高的用藥依從性而日益受到關注。在治療應用方面，第2型糖尿病的治療仍然是成長最快的細分市場，這主要得益於第2型糖尿病的高發生率以及GLP-1促效劑在血糖值管理方面的有效性。

體重管理正成為第二大成長領域，因為GLP-1促效劑在減重和代謝健康方面均有效。人們對旨在透過協同效應改善治療效果的聯合治療的興趣也日益濃厚。藥物遞送系統的技術創新正透過改善患者體驗和治療效果，進一步推動市場成長。此外，研發投入的增加也促進了創新，從而催生出療效和安全性更高的新一代GLP-1促效劑。

GLP-1促效劑市場呈現多元化的市場佔有率趨勢，成熟企業和新興企業都在爭奪主導。定價策略差異顯著，受產品創新和競爭定位的影響。近期推出的產品引進了新的配方，提高了治療效果和患者遵從性。市場正朝著個人化醫療的方向發展，以滿足個別患者的特定需求和偏好。這種發展趨勢推動了研發投入的增加，重點在於最佳化給藥機制和改善病患療效。

GLP-1促效劑市場的競爭日益激烈，主要企業透過技術創新和策略聯盟來凸顯自身優勢。法規結構，尤其是在北美和歐洲，對市場動態的塑造起著至關重要的作用。遵守嚴格的監管準則對於市場准入和永續性至關重要。專利到期導致的學名藥上市也對市場競爭格局產生了影響。市場分析強調了策略聯盟和創新在維持競爭優勢的重要性。法規環境持續變化，為參與企業帶來了挑戰和機會。

主要趨勢和促進因素：

受全球糖尿病和肥胖症盛行率上升的推動，GLP-1促效劑市場正經歷強勁成長。人們對GLP-1促效劑在血糖值管理和減重方面的有效性認知不斷提高，進一步促進了這一快速成長。此外，藥物遞送系統的進步，提高了患者的依從性和治療效果，也推動了市場擴張。

口服GLP-1促效劑的研發是關鍵趨勢，它拓展了注射藥物以外的治療選擇。這項創新有望擴大患者群體並加速市場成長。此外，製藥公司之間的合作與夥伴關係正在加速研發進程，從而推出新的製劑。

此外，數位健康技術的整合增強了患者監測和參與度，從而提高了治療依從性。隨著基於基因和表現型數據的個人化醫療日益受到關注，個人化醫療領域湧現出新的機會。專注於這些創新技術的公司有望佔據可觀的市場佔有率。隨著對有效糖尿病管理方案的需求不斷成長，GLP-1促效劑市場預計將持續成長。

壓制與挑戰：

目前，GLP-1促效劑市場面臨許多重大限制與挑戰。首要問題是GLP-1促效劑治療費用高昂，限制了患者的用藥，尤其是在低收入地區。此外，患者和醫護人員對GLP-1促效劑的益處和潛在副作用缺乏足夠的認知和了解，也阻礙了其應用。監管壁壘和冗長的核准流程也阻礙了市場擴張，企業面臨嚴格的核准要求和產品上市的延遲。其他療效相當且價格可能更低的替代治療方法的存在也對市場構成挑戰。最後，受全球事件影響，供應鏈中斷加劇，影響了這些藥物的穩定供應，對生產者和消費者都帶來了巨大挑戰。所有這些因素共同構成了GLP-1促效劑市場成長和應用的重大障礙。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 基於胜肽的GLP-1促效劑
    • 非胜肽類GLP-1促效劑
  • 市場規模及預測：依產品分類
    • 注射用GLP-1促效劑
    • 口服GLP-1促效劑
  • 市場規模及預測：依技術分類
    • 重組DNA技術
    • 合成技術
    • 生物技術
  • 市場規模及預測：依應用領域分類
    • 2型糖尿病
    • 肥胖管理
    • 心血管疾病
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 醫療設施
    • 居家醫療環境
    • 研究所
  • 市場規模及預測：依組件分類
    • 藥物中的活性成分
    • 添加劑
    • 包裝材料
  • 市場規模及預測：依設備分類
    • 筆式注射器
    • 預填充式注射器
    • 自動注射器
  • 市場規模及預測：依市場細分
    • 住院患者
    • 門診治療環境
  • 市場規模及預測：依發展階段分類
    • 藥物發現
    • 臨床前階段
    • 臨床試驗
    • 商業化
  • 市場規模及預測：按解決方案分類
    • 患者用藥依從性解決方案
    • 數位健康平台

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Novo Nordisk
  • Eli Lilly and Company
  • AstraZeneca
  • Sanofi
  • Boehringer Ingelheim
  • Intarcia Therapeutics
  • Hanmi Pharmaceutical
  • Zydus Cadila
  • Oramed Pharmaceuticals
  • Adocia
  • Chugai Pharmaceutical
  • Dong-A ST
  • Emisphere Technologies
  • Amgen
  • Pfizer
  • Luye Pharma Group
  • GSK
  • Takeda Pharmaceutical Company
  • MannKind Corporation
  • Biocon

第9章 關於我們

簡介目錄
Product Code: GIS33124

GLP-1 Agonist Market is anticipated to expand from $53.0 Billion in 2024 to $264.9 Billion by 2034, growing at a CAGR of approximately 17.5%. The GLP-1 Agonist Market centers on medications that mimic the glucagon-like peptide-1 hormone, enhancing insulin secretion and glucose regulation. Primarily used for type 2 diabetes and obesity management, these agonists are pivotal in metabolic therapy. With rising diabetes prevalence and increasing obesity rates, the market is experiencing robust growth, spurred by advancements in drug formulations and delivery mechanisms, alongside expanding therapeutic applications.

The GLP-1 Agonist Market is navigating a complex landscape shaped by global tariffs and geopolitical tensions. In Japan and South Korea, companies are strategizing to mitigate the impact of tariffs by increasing investments in local R&D and production capabilities. China, under export restrictions, is accelerating its focus on domestic pharmaceutical innovation to ensure supply chain resilience. Taiwan, while maintaining its pivotal role in pharmaceutical manufacturing, is vulnerable to geopolitical tensions, particularly those involving the US and China. The parent market is witnessing robust growth globally, driven by rising demand for diabetes and obesity treatments. By 2035, the market is poised for significant expansion, contingent on strategic alliances and diversified supply chains. Middle East conflicts may indirectly influence energy prices, affecting manufacturing costs and timelines.

Market Segmentation
TypePeptide-based GLP-1 Agonists, Non-peptide GLP-1 Agonists
ProductInjectable GLP-1 Agonists, Oral GLP-1 Agonists
TechnologyRecombinant DNA Technology, Synthetic Technology, Biotechnology
ApplicationType 2 Diabetes, Obesity Management, Cardiovascular Disease
End UserHospitals, Clinics, Homecare Settings, Research Institutes
ComponentActive Pharmaceutical Ingredients, Excipients, Packaging Materials
DevicePen Injectors, Prefilled Syringes, Autoinjectors
DeploymentIn-patient Settings, Out-patient Settings
StageDiscovery, Preclinical, Clinical Trials, Commercialization
SolutionsPatient Adherence Solutions, Digital Health Platforms

The GLP-1 Agonist Market is experiencing robust expansion, propelled by rising demand for innovative diabetes management solutions. The pharmaceutical segment dominates, with injectable formulations leading due to their efficacy in glycemic control. Oral formulations are gaining momentum, offering convenience and improved patient adherence. Within therapeutic applications, type 2 diabetes treatment remains the top-performing sub-segment, driven by its prevalence and the efficacy of GLP-1 agonists in managing blood glucose levels.

Weight management emerges as the second-highest performing sub-segment, reflecting the dual benefits of GLP-1 agonists in weight reduction and metabolic health. The market is also witnessing increased interest in combination therapies, enhancing treatment outcomes through synergistic effects. Technological advancements in drug delivery systems are further propelling market growth, improving patient experience and therapeutic outcomes. Additionally, growing investments in research and development are fostering innovation, paving the way for next-generation GLP-1 agonists with enhanced efficacy and safety profiles.

GLP-1 Agonist Market is characterized by diverse market share dynamics, with established players and emerging companies vying for dominance. Pricing strategies vary significantly, influenced by product innovation and competitive positioning. Recent product launches have introduced novel formulations, enhancing therapeutic efficacy and patient compliance. The market is witnessing a shift towards personalized medicine, catering to specific patient needs and preferences. This evolution is fostering increased investment in research and development, with a focus on optimizing delivery mechanisms and patient outcomes.

Competition in the GLP-1 Agonist Market is intensifying, with key players differentiating through technological advancements and strategic partnerships. Regulatory frameworks, particularly in North America and Europe, play a pivotal role in shaping market dynamics. Compliance with stringent guidelines is crucial for market entry and sustainability. The competitive landscape is further influenced by patent expirations, driving generic drug introductions. Market analysis underscores the importance of strategic alliances and innovation in maintaining competitive advantage. The regulatory environment continues to evolve, presenting both challenges and opportunities for market participants.

Geographical Overview:

The GLP-1 agonist market is witnessing robust growth across various regions, each presenting unique opportunities. North America remains at the forefront, driven by rising obesity rates and a strong focus on diabetes management. The region's healthcare infrastructure and ongoing research initiatives further bolster market expansion. Europe follows closely, with an increasing prevalence of lifestyle-related diseases and a growing elderly population.

Regulatory support and reimbursement policies in Europe enhance market penetration. In the Asia Pacific, the market is expanding rapidly due to rising healthcare awareness and improving access to medical care. Countries like China and India are emerging as lucrative markets, driven by large patient populations and increasing healthcare expenditure. Latin America and the Middle East & Africa are also showing promise. These regions are experiencing an uptick in healthcare investments and a growing emphasis on chronic disease management. Brazil and Saudi Arabia are poised as key emerging markets, offering substantial growth potential.

Recent Developments:

In recent months, the GLP-1 agonist market has experienced pivotal developments, underscoring its burgeoning potential. Novo Nordisk announced a strategic collaboration with a biotech startup to enhance its GLP-1 pipeline, aiming to accelerate the development of next-generation therapies. This partnership is expected to bolster Novo Nordisk's position in the market, leveraging innovative technologies to address unmet medical needs.

Meanwhile, Eli Lilly reported a significant expansion of its manufacturing facilities, specifically to increase the production capacity of its GLP-1 agonist products. This move comes in response to rising global demand, reflecting the growing acceptance and utilization of GLP-1 therapies in managing diabetes and obesity.

Regulatory advancements have also been noteworthy, with the European Medicines Agency granting a fast-track designation to a novel GLP-1 agonist, highlighting its potential to transform treatment paradigms. In parallel, Pfizer has entered a joint venture with a leading Asian pharmaceutical company to penetrate emerging markets, focusing on the distribution and accessibility of GLP-1 agonists.

Moreover, the market witnessed a significant merger, with two mid-sized pharmaceutical companies joining forces to pool resources and expertise in GLP-1 research and development. This consolidation aims to streamline operations and foster innovation, potentially leading to groundbreaking therapies.

Lastly, a prominent investment firm announced a substantial financial commitment to a biotech company specializing in GLP-1 agonists, underscoring investor confidence in the market's growth trajectory. These developments collectively signify a dynamic and rapidly evolving landscape, with companies strategically positioning themselves to capitalize on the opportunities within the GLP-1 agonist market.

Key Trends and Drivers:

The GLP-1 Agonist Market is experiencing robust growth, spurred by rising prevalence of diabetes and obesity globally. This surge is driven by increasing awareness of GLP-1 agonists\u2019 efficacy in managing blood glucose levels and promoting weight loss. The market is also benefiting from advancements in drug delivery systems, enhancing patient compliance and treatment outcomes.

Key trends include the development of oral GLP-1 agonists, expanding treatment options beyond injectable forms. This innovation is expected to broaden the patient base and drive market expansion. Additionally, collaborations and partnerships among pharmaceutical companies are accelerating research and development efforts, leading to the introduction of novel formulations.

Furthermore, the integration of digital health technologies is enhancing patient monitoring and engagement, improving adherence to therapy. Opportunities are emerging in personalized medicine, where tailored treatments based on genetic and phenotypic data are gaining traction. Companies focusing on these innovations are poised to capture significant market share. With the rising demand for effective diabetes management solutions, the GLP-1 Agonist Market is set for continued growth.

Restraints and Challenges:

The GLP-1 Agonist Market is currently navigating several significant restraints and challenges. A predominant issue is the high cost associated with GLP-1 agonist therapies, which limits accessibility for patients, particularly in low-income regions. Additionally, there exists a substantial lack of awareness and understanding among both patients and healthcare providers regarding the benefits and potential side effects of GLP-1 agonists, hindering their adoption. Regulatory hurdles and lengthy approval processes further complicate market expansion, as companies face stringent requirements that delay product launches. The market is also challenged by the presence of alternative treatments and therapies, which offer competitive efficacy at potentially lower costs. Lastly, supply chain disruptions, exacerbated by global events, have impacted the consistent availability of these medications, posing a significant challenge for both manufacturers and consumers. These factors collectively pose formidable barriers to the growth and widespread adoption of GLP-1 agonists.

Key Companies:

Novo Nordisk, Eli Lilly and Company, AstraZeneca, Sanofi, Boehringer Ingelheim, Intarcia Therapeutics, Hanmi Pharmaceutical, Zydus Cadila, Oramed Pharmaceuticals, Adocia, Chugai Pharmaceutical, Dong-A ST, Emisphere Technologies, Amgen, Pfizer, Luye Pharma Group, GSK, Takeda Pharmaceutical Company, MannKind Corporation, Biocon

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Component
  • 2.7 Key Market Highlights by Device
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Stage
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Peptide-based GLP-1 Agonists
    • 4.1.2 Non-peptide GLP-1 Agonists
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Injectable GLP-1 Agonists
    • 4.2.2 Oral GLP-1 Agonists
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Recombinant DNA Technology
    • 4.3.2 Synthetic Technology
    • 4.3.3 Biotechnology
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Type 2 Diabetes
    • 4.4.2 Obesity Management
    • 4.4.3 Cardiovascular Disease
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Clinics
    • 4.5.3 Homecare Settings
    • 4.5.4 Research Institutes
  • 4.6 Market Size & Forecast by Component (2020-2035)
    • 4.6.1 Active Pharmaceutical Ingredients
    • 4.6.2 Excipients
    • 4.6.3 Packaging Materials
  • 4.7 Market Size & Forecast by Device (2020-2035)
    • 4.7.1 Pen Injectors
    • 4.7.2 Prefilled Syringes
    • 4.7.3 Autoinjectors
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 In-patient Settings
    • 4.8.2 Out-patient Settings
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Discovery
    • 4.9.2 Preclinical
    • 4.9.3 Clinical Trials
    • 4.9.4 Commercialization
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Patient Adherence Solutions
    • 4.10.2 Digital Health Platforms

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Component
      • 5.2.1.7 Device
      • 5.2.1.8 Deployment
      • 5.2.1.9 Stage
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Component
      • 5.2.2.7 Device
      • 5.2.2.8 Deployment
      • 5.2.2.9 Stage
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Component
      • 5.2.3.7 Device
      • 5.2.3.8 Deployment
      • 5.2.3.9 Stage
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Component
      • 5.3.1.7 Device
      • 5.3.1.8 Deployment
      • 5.3.1.9 Stage
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Component
      • 5.3.2.7 Device
      • 5.3.2.8 Deployment
      • 5.3.2.9 Stage
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Component
      • 5.3.3.7 Device
      • 5.3.3.8 Deployment
      • 5.3.3.9 Stage
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Component
      • 5.4.1.7 Device
      • 5.4.1.8 Deployment
      • 5.4.1.9 Stage
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Component
      • 5.4.2.7 Device
      • 5.4.2.8 Deployment
      • 5.4.2.9 Stage
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Component
      • 5.4.3.7 Device
      • 5.4.3.8 Deployment
      • 5.4.3.9 Stage
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Component
      • 5.4.4.7 Device
      • 5.4.4.8 Deployment
      • 5.4.4.9 Stage
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Component
      • 5.4.5.7 Device
      • 5.4.5.8 Deployment
      • 5.4.5.9 Stage
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Component
      • 5.4.6.7 Device
      • 5.4.6.8 Deployment
      • 5.4.6.9 Stage
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Component
      • 5.4.7.7 Device
      • 5.4.7.8 Deployment
      • 5.4.7.9 Stage
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Component
      • 5.5.1.7 Device
      • 5.5.1.8 Deployment
      • 5.5.1.9 Stage
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Component
      • 5.5.2.7 Device
      • 5.5.2.8 Deployment
      • 5.5.2.9 Stage
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Component
      • 5.5.3.7 Device
      • 5.5.3.8 Deployment
      • 5.5.3.9 Stage
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Component
      • 5.5.4.7 Device
      • 5.5.4.8 Deployment
      • 5.5.4.9 Stage
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Component
      • 5.5.5.7 Device
      • 5.5.5.8 Deployment
      • 5.5.5.9 Stage
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Component
      • 5.5.6.7 Device
      • 5.5.6.8 Deployment
      • 5.5.6.9 Stage
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Component
      • 5.6.1.7 Device
      • 5.6.1.8 Deployment
      • 5.6.1.9 Stage
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Component
      • 5.6.2.7 Device
      • 5.6.2.8 Deployment
      • 5.6.2.9 Stage
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Component
      • 5.6.3.7 Device
      • 5.6.3.8 Deployment
      • 5.6.3.9 Stage
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Component
      • 5.6.4.7 Device
      • 5.6.4.8 Deployment
      • 5.6.4.9 Stage
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Component
      • 5.6.5.7 Device
      • 5.6.5.8 Deployment
      • 5.6.5.9 Stage
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Novo Nordisk
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Eli Lilly and Company
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 AstraZeneca
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Sanofi
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Boehringer Ingelheim
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Intarcia Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Hanmi Pharmaceutical
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Zydus Cadila
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Oramed Pharmaceuticals
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Adocia
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Chugai Pharmaceutical
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Dong-A ST
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Emisphere Technologies
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Amgen
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Pfizer
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Luye Pharma Group
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 GSK
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Takeda Pharmaceutical Company
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 MannKind Corporation
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Biocon
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us